4568:TYO
Daiichi Sankyo Co Ltd
Â¥2,845.50
arrow_upward
+2.65%(+73.50) 1D
Sep 14, 3:30:00 PM GMT+9 · JPY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4568...
Open
Â¥2,722
High
Â¥2,846
Low
Â¥2,722
Mkt. cap
5.30T
Avg. vol.
6.35M
Volume
5.95M
Dividend
2.74%
Quarterly dividend
Â¥19
P/E ratio
21.55
52-wk high
Â¥4,178
52-wk low
Â¥2,390
EPS
Â¥132
Shares outstanding
647.77M
No. of employees
20K
Open
Â¥2,722
High
Â¥2,846
Low
Â¥2,722
Mkt. cap
5.30T
Avg. vol.
6.35M
Volume
5.95M
Dividend
2.74%
Quarterly dividend
Â¥19
P/E ratio
21.55
52-wk high
Â¥4,178
52-wk low
Â¥2,390
EPS
Â¥132
Shares outstanding
647.77M
No. of employees
20K
News stories
From web sources and news partners
Investing.com UK
·
11 hours ago
Enhertu shows progression-free survival benefit in lung cancer trial By Investing.com
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees20.2K
FoundedSep 28, 2005
HeadquartersChuo City, Tokyo, Japan
Sector-
Websitedaiichisankyo.co.jp